{"filing":{"accession_number":"0001815776-26-000046","cik":"0001815776","ticker":"LENZ","company_name":"LENZ Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"lenz-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000046/lenz-20260630.htm"},"events":[{"id":15969,"run_id":14244,"accession_number":"0001815776-26-000046","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The disclosure centers on Zach Scheiner's resignation from the Board of Directors and all Board committees, effective immediately on June 30, 2026. While the filing also mentions Jeff George's appointment to the Audit Committee, the principal action disclosed is Dr. Scheiner's departure. Board-level departures are material governance events affecting investor assessment of the company's leadership and oversight structure.","company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13903,"accession_number":"0001815776-26-000046","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on Zach Scheiner's resignation from the Board of Directors and all Board committees, effective immediately on June 30, 2026. While the filing also mentions Jeff George's appointment to the Audit Committee, the principal action disclosed is Dr. Scheiner's departure. Board-level departures are material governance events affecting investor assessment of the company's leadership and oversight structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:02:36.101572+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13903,"accession_number":"0001815776-26-000046","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on Zach Scheiner's resignation from the Board of Directors and all Board committees, effective immediately on June 30, 2026. While the filing also mentions Jeff George's appointment to the Audit Committee, the principal action disclosed is Dr. Scheiner's departure. Board-level departures are material governance events affecting investor assessment of the company's leadership and oversight structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:02:36.101572+00:00","company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","filing_date":"2026-07-02"}]}